At the cutting edge of biotechnology

iX Biopharma focuses on the development and commercialisation of novel wafer formulations to improve the quality of life of those suffering from pain and other health conditions

Published Fri, Sep 18, 2020 · 09:50 PM

iX Biopharma

SINCE joining Singapore Exchange (SGX)-listed specialty pharmaceutical company iX Biopharma, Janakan Krishnarajah has been getting involved in many new aspects of the drug making business.

Dr Krishnarajah, a specialist in the fields of clinical pharmacology and internal medicine, had previously held the position of CEO and medical director at Linear Clinical Research - an Australian clinical trials facility.

There, the 42-year-old developed extensive experience in Phases I-IV clinical trials. He acted as principal or co-investigator in more than a hundred Phase I-II clinical trials.

In April 2016, Dr Krishnarajah joined iX Biopharma as chief medical officer. He was promoted to chief operating officer three years later. "Previously, although I designed and ran the clinical trials, I never got to see the final stage, as companies would take the successful products to register them in their respective countries. Now at iX, I'm involved in th…